Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials Review uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Epilepsy
  • Glioma
  • Seizures

abstract

  • Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

publication date

  • January 2017

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5193028

Digital Object Identifier (DOI)

  • 10.1093/neuonc/now190

PubMed ID

  • 27651472

Additional Document Info

start page

  • 12

end page

  • 21

volume

  • 19

number

  • 1